• L Arnaud, A Mathian, D Adoue, B Bader-Meunier, V Baudouin, C Belizna, B Bonnotte, F Boumedine, A Chaib, M Chauchard, L Chiche, E Daugas, A Ghali, P Gobert, G Gondran, G Guettrot-Imbert, E Hachulla, M Hamidou, J Haroche, B Hervier, A Hummel, N Jourde-Chiche, A-S Korganow, T Kwon, V Le Guern, A Le Quellec, N Limal, N Magy-Bertrand, P Marianetti-Guingel, T Martin, N Martin Silva, O Meyer, M Miyara, S Morell-Dubois, J Ninet, T Papo, J-L Pennaforte, K Polomat, J Pourrat, V Queyrel, I Raymond, P Remy, K Sacre, J Schmidt, J Sibilia, J-F Viallard, A Viau Brabant, D Wahl, E Bruckert, Z Amoura, and groupe France Lupus Érythémateux systémique Réseau (FLEUR) et les centres de référence et de compétence des lupus et syndromes des antiphospholipides.
• Service de médecine interne 2, Centre national de référence du lupus systémique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Sorbonne universités, UPMC université Paris 06, 75013 Paris, France. Electronic address: laurent.arnaud@psl.aphp.fr.
• Rev Med Interne. 2015 Jun 1; 36 (6): 372380372-80.

PurposeTo develop French recommendations about screening and management of cardiovascular risk factors in systemic lupus erythematosus (SLE).MethodsThirty-nine experts qualified in internal medicine, rheumatology and nephrology have selected recommendations from a list developed based on evidence from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified.ResultsExperts recommended an annual screening of cardiovascular risk factors in SLE. Statins should be prescribed for primary prevention in SLE patients based on the level of LDL-cholesterol and the number of cardiovascular risk factors, considering SLE as an additional risk factor. For secondary prevention, experts have agreed on an LDL-cholesterol target of <0.7 g/L. Hypertension should be managed according to the 2013 European guidelines, using renin-angiotensin system blockers as first line agents in case of renal involvement. Aspirin can be prescribed in patients with high cardiovascular risk or with antiphospholipid antibodies.ConclusionThese recommendations about the screening and management of cardiovascular risk factors in SLE can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of SLE patients.Copyright © 2014 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

22 keywords...

hide…